Alumis

Goal disorientation and lack of vision
Biotech

Alumis crushed by midstage lupus flop but plots path to phase 3

Alumis is moving the TYK2 inhibitor into phase 3 in lupus, pointing to evidence of efficacy in a prespecified subgroup to support its decision.
Nick Paul Taylor Sep 1, 2026 9:27am
for sale sign

Alumis pulls back from would-be rival to Amgen’s Tepezza

May 15, 2026 3:44am
Graphic image of an arrow nailing the bullseye of a target

Alumis beams as pivotal data on Sotyktu rival drive stock surge

Jan 6, 2026 9:05am
parasailing over clouds in Salzburg Austria

Sarepta shakes up C-suite amid org overhaul—Chutes & Ladders

Jul 18, 2025 8:30am
merge MA railway train tracks path together

Activist investor fails to derail Alumis' Acelyrin merger

May 14, 2025 7:45am
Graphic image of a red thumbs down against a blue background

Investor pressures Acelyrin to exit Alumis merger and liquidate

Apr 30, 2025 10:30am